A Phase 3 interventional study of Verteporfin photodynamic therapy and Pegaptanib in Macular Degeneration and Choroidal Neovascularization, sponsored by Novartis Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2016-03-31.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing Triamcinolone Acetonide in Macular Degeneration — none open to participants now, none under way, none of them phase 3. Triamcinolone Acetonide · Macular Degeneration.
Among the 12 studies testing Triamcinolone Acetonide in Macular Degeneration, this one is the 4th largest by enrollment of the 10 interventional ones that give a count, is one of 3 that started in 2005, is one of 4 in phase 3, and was the 6th registered.
1,459 studies on the registry are indexed under Macular Degeneration; 236 are open to participants now.
Browse Macular Degeneration studies →None of the 12 studies testing Triamcinolone Acetonide in Macular Degeneration is open now. The open studies under Macular Degeneration, anywhere →
Triamcinolone Acetonide: first FDA approval 1958 (TRIAMCINOLONE ACETONIDE). What it is approved for, and how studies give it, is on its page →
Of the 166 Macular Degeneration studies recruiting now, 117 (70%) set no upper age limit and 5 (3%) stop at 75 or younger; 19 take children under 18; 35 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 6 · Phase 4 1
First in 2003; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 111 is above the median of 56 across 985 interventional studies indexed under Macular Degeneration.
Median enrollment 68 across the 10 interventional studies. Of the 5 that completed or were terminated, 1 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 12 have an industry lead sponsor. The 9 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
81 studies in Macular Degeneration by Novartis: 1 open now, 1 under way, none of them phase 3. Of 79 finished, 41 (52%) have results posted.
Among the 81 studies in Macular Degeneration by Novartis, this one is the 31st largest by enrollment of the 56 interventional ones that give a count, is one of 4 that started in 2005, is one of 23 in phase 3, and was the 3rd registered.
Novartis’s Macular Degeneration studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 12 studies testing Triamcinolone Acetonide in Macular Degeneration, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Novartis’s 81 in Macular Degeneration:
This tab as a report to print or save as PDF → With an account.
To evaluate the safety and efficacy of the combination treatments in wet age-related macular degeneration. The combination treatment consists of verteporfin photodynamic therapy and either triamcinolone acetonide or pegaptanib added as an intravitreal injection.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Other protocol-specified inclusion/exclusion criteria applied.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received Verteporfin photodynamic therapy and 1 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 1 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
Drug: Verteporfin photodynamic therapy · Drug: Triamcinolone acetonide
Participants received Verteporfin photodynamic therapy and 4 mg triamcinolone acetonide intravitreal injection at the baseline visit. After the baseline visit, these participants received Verteporfin and triamcinolone acetonide 4 mg at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. At the 1.5, 4.5, 7.5 and 10.5 month follow-up visits participants received a sham injection. Starting from Month 12, if patients experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigators' discretion with available standard of care therapy.
Drug: Verteporfin photodynamic therapy · Drug: Triamcinolone acetonide
Participants received Verteporfin photodynamic therapy and 0.3 mg Pegaptanib at the baseline visit. After the baseline visit, these participants received pegaptanib every 1.5 months up until and including the 10.5 month visit. After the baseline visit, these participants also received verteporfin at every 3 month visit up to Month 9 only if leakage was detected on the fluorescein angiogram. Starting from Month 12, if participants experienced ≥ 10 letters vision loss from the previous visit, they were treated at the investigator's discretion with available standard of care therapy.
Drug: Verteporfin photodynamic therapy · Drug: Pegaptanib
After a 10-minute intravenous infusion of verteporfin at a dose of 6 mg/m\^2 body surface area, verteporfin was activated by light application of 50 J/cm\^2 to the study eye, begun 15 minutes after the start of infusion.
Also known as: Visudyne
Pegaptanib sodium 0.3 mg administered by intravitreal injection.
Also known as: Macugen
Triamcinolone acetonide administered by intravitreal injection.
Also known as: Kenalog-40®
Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline.
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. A decrease in score indicates worsening of vision. This outcome assessed the percentage of participants who lost less than 15 letters of visual acuity at 12 months as compared with baseline.
Time frame: Baseline to Month 12
Percentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 12
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 5 or more letters of visual acuity at 12 months compared with baseline.
Time frame: Baseline to Month 12
Percentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 10 or more letters of visual acuity at 12 months as compared with baseline.
Time frame: Baseline to Month 12
Percentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 12
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at 12 months as compared with baseline.
Time frame: Baseline to Month 12
Number of Participants Requiring Verteporfin Treatment Throughout the Study
Participants received study drug at the Baseline visit and subsequent retreatment at 3 month intervals if leakage was detected on the fluorescein angiogram. The cumulative distribution of the number of treatments is shown per arm.
Time frame: Baseline to Month 12
Mean Change From Baseline in Total Area of Lesion at 12 Months
Fluorescein angiography (FA) was used to assess total lesion area. All angiographs were sent to the Central Reading Center (CRC) for analysis.
Time frame: Baseline to Month 12
The protocol was amended to limit the sample size from 339 to 100. 111 entered the study and and were part of the 12 mo analysis. The study was subsequently terminated. The patients did not receive study drug during the second year of the study.
| Milestone | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib |
|---|---|---|---|
| Started | 32 | 41 | 38 |
| Completed | 22 | 29 | 24 |
| Not completed | 10 | 12 | 14 |
| Withdrew: Adverse event | 3 | 0 | 2 |
| Withdrew: Unsatisfactory therapeutic effect | 4 | 5 | 5 |
| Withdrew: Protocol violation | 0 | 0 | 1 |
| Withdrew: Subject withdrew consent | 2 | 2 | 5 |
| Withdrew: Lost to follow-up | 0 | 3 | 0 |
| Withdrew: Death | 1 | 2 | 1 |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. A decrease in score indicates worsening of vision. This outcome assessed the percentage of participants who lost less than 15 letters of visual acuity at 12 months as compared with baseline.
| Percentage of Participants | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib |
|---|---|---|---|
| Percentage of Participants Who Lose Less Than 15 Letters of Best Corrected Visual Acuity (BCVA) at 12 Months From Baseline. | 59.4 | 63.4 | 71.1 |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 5 or more letters of visual acuity at 12 months compared with baseline.
| Percentage of Participants | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib |
|---|---|---|---|
| Percentage of Participants With Gain of 5 or More Letters of Best Corrected Visual Acuity From Baseline to Month 12 | 31.3 | 12.2 | 28.9 |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 10 or more letters of visual acuity at 12 months as compared with baseline.
| Percentage of Participants | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib |
|---|---|---|---|
| Percentage of Participants With Gain of BCVA of 10 or More Letters at 12 Months | 18.8 | 2.4 | 23.7 |
BCVA score was based on the number of letters read correctly on the Early Treatment Diabetic Retinopathy Study (ETDRS) visual acuity chart assessed at a starting distance of 4 meters. An ETDRS visual acuity score of 85 is approximately 20/20. An increased score indicates improvement in acuity. This outcome assessed the percentage of participants who gained 15 or more letters of visual acuity at 12 months as compared with baseline.
| Percentage of Participants | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib |
|---|---|---|---|
| Percentage of Participants With Gain of BCVA Score of 15 or More Letters at Month 12 | 6.3 | 0 | 13.2 |
Participants received study drug at the Baseline visit and subsequent retreatment at 3 month intervals if leakage was detected on the fluorescein angiogram. The cumulative distribution of the number of treatments is shown per arm.
| Participants | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib |
|---|---|---|---|
| Participants who received 1 treatment | 11 ± 0 | 12 ± 0 | 10 ± 0 |
| Participants who received 2 treatments | 10 | 15 | 19 |
| Participants who received 3 treatments | 9 | 12 | 5 |
| Participants who received 4 treatments | 2 | 2 | 4 |
Fluorescein angiography (FA) was used to assess total lesion area. All angiographs were sent to the Central Reading Center (CRC) for analysis.
| mm^2 | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib |
|---|---|---|---|
| Baseline | 6.9178 ± 5.9455 | 5.6400 ± 3.7154 | 6.3011 ± 5.4794 |
| 12 Months | 6.8959 ± 7.6848 | 5.8149 ± 4.6465 | 8.6245 ± 7.1242 |
| Change from Baseline | -0.0219 ± 7.7026 | 0.1749 ± 4.2357 | 2.3234 ± 5.9370 |
Collected over 12 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Verteporfin + 1 mg Triamcinolone | — | 11/32 (34.4%) | 32/32 (100%) |
| Verteporfin + 4 mg Triamcinolone | — | 9/41 (22%) | 38/41 (92.7%) |
| Verteporfin + Pegaptanib | — | 10/38 (26.3%) | 30/38 (78.9%) |
| Event | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib |
|---|---|---|---|
| ACCIDENTAL INJURYInjury, poisoning and procedural complications | 2/32 | 1/41 | 3/38 |
| GASTROINTESTINAL DISORDERGastrointestinal disorders | 1/32 | 0/41 | 2/38 |
| PNEUMONIAInfections and infestations | 1/32 | 2/41 | 2/38 |
| CORONARY ARTERY DISORDERCardiac disorders | 0/32 | 2/41 | 1/38 |
| CEREBRAL INFARCTNervous system disorders | 0/32 | 2/41 | 0/38 |
| ANAPHYLACTOID REACTIONImmune system disorders | 1/32 | 0/41 | 0/38 |
| INFECTIONInfections and infestations | 1/32 | 0/41 | 0/38 |
| NEOPLASMNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/32 | 0/41 | 0/38 |
| ARTERIAL THROMBOSISVascular disorders | 1/32 | 0/41 | 0/38 |
| ARTERIOSCLEROSISVascular disorders | 1/32 | 0/41 | 0/38 |
| Event | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib |
|---|---|---|---|
| CATARACT (Study eye)Eye disorders | 8/32 | 10/41 | 2/38 |
| HYPERTENSIONVascular disorders | 7/32 | 7/41 | 2/38 |
| AMD PROGRESSION (Study eye)Eye disorders | 6/32 | 8/41 | 3/38 |
| AMD PROGRESSION (Fellow eye)Eye disorders | 5/32 | 6/41 | 7/38 |
| EYE HEMORRHAGE (Study eye)Eye disorders | 5/32 | 7/41 | 7/38 |
| ACUTE ELEVATED IOP (Study eye)Eye disorders | 2/32 | 7/41 | 0/38 |
| INFECTIONInfections and infestations | 5/32 | 2/41 | 0/38 |
| PAINGeneral disorders | 5/32 | 4/41 | 3/38 |
| RHINITISInfections and infestations | 3/32 | 6/41 | 2/38 |
| ACCIDENTAL INJURYInjury, poisoning and procedural complications | 0/32 | 2/41 | 5/38 |
| Age, Continuous(years) | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib | Total |
|---|---|---|---|---|
| Mean | 76 ± 9 | 78 ± 8 | 81 ± 6 | 78 ± 8 |
| Sex: Female, Male(Participants) | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib | Total |
|---|---|---|---|---|
| Female | 18 | 25 | 20 | 63 |
| Male | 14 | 16 | 18 | 48 |
| Region of Enrollment(participants) | Verteporfin + 1 mg Triamcinolone | Verteporfin + 4 mg Triamcinolone | Verteporfin + Pegaptanib | Total |
|---|---|---|---|---|
| United States | 32 | 41 | 38 | 111 |
The record gives a start of Sep 2005 and a primary completion of Jan 2008. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 3 years 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Triamcinolone Acetonide